In Brief: Preamendment Class III device classification
This article was originally published in The Gray Sheet
Executive SummaryPreamendment Class III device classification: FDA has received data from approximately 10% of manufacturers required to submit safety and effectiveness information by the Aug. 14 deadline under the agency's August 1995 call for data on pre-1976 Class III devices per section 515(i) of the FD&C Act ("The Gray Sheet" Aug. 21, 1995, p. 6). The data, for preamendment devices for which FDA has not yet issued a call for PMAs, will be used by the agency to determine which devices will remain in Class III and which can be downclassified. FDA's Office of Device Evaluation sent a letter the week of July 29 to 98 firms registered as manufacturers of the 17 devices covered by the Aug. 14 deadline, reminding them of the impending due date. For further information, contact ODE's Melpi Jeffries at 301/594-2186...
You may also be interested in...
Oncology R&D isn’t waning, but investment in neurology and psychiatry drug development are paying off in new drug approvals. Rapid growth in CDER non-malignant hematology approvals reflects longer, broader trend toward orphan drugs.
We clean out your Martin Luther King Day inbox so you don't have to.
Political worries aside, industry is confidently executing on focused strategies as it welcomes a new decade, even if a lack of deal news at the J.P. Morgan Healthcare Conference didn't excite investors.